

2015-2019 U.S. Cancer Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies

<https://marketpublishers.com/r/2B2B115619AEN.html>

Date: September 2015

Pages: 620

Price: US\$ 7,840.00 (Single User License)

ID: 2B2B115619AEN

Abstracts

Complete report \$9,800. DataPack (test volumes, sales forecasts, supplier shares) \$6,400. 2015-2019 U.S. Cancer Diagnostics Market is a new strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in the US cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers. Rationale The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion. Business Opportunities and Strategic Recommendations- Specific new product development opportunities with potentially significant market appeal during the next five years. - Design criteria for new products. - Alternative market penetration strategies.

Potential market entry barriers and risks. Cancer Diagnostic Tests—Over 200 current and emerging assays including: ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons,

Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others. Market Segmentation Analysis- Sales and market shares of major suppliers, by individual cancer diagnostic test. - Five-year test volume and sales forecasts for major cancer diagnostic tests by market segment, including:- Hospitals- Commercial/Private Laboratories- Physician Offices/Group Practices- Cancer Clinics- Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers. - Cancer statistics, etiology and recent developments. Current and Emerging Products- Review of over 200 current and emerging cancer diagnostic tests, including:- Biochemical Markers- Oncogenes- Growth Factors- Hormones- Colony Stimulating Factors- Lymphokines- Immunohistochemical Stains, and others. - Analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices. Technology Review- Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing. - Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy. - Extensive listings of over 500 companies, universities and research centers developing new cancer diagnostic tests and detection technologies. Competitive Assessments- Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D. Contains 620 pages and 103 tables

Contents

1. INTRODUCTION

2. WORLDWIDE MARKET OVERVIEW

1. MARKET OVERVIEW
2. WORLDWIDE MARKET STRUCTURE
3. WORLDWIDE MARKET SIZE AND GROWTH

3. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

4. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

5. ALTERNATIVE MARKET PENETRATION STRATEGIES

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies

6. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

7. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

- A. Cancer Statistics and Etiology

1. BREAST CANCER
 2. LUNG CANCER
 3. COLON AND RECTUM CANCER
 4. PROSTATE CANCER
 5. STOMACH CANCER
 6. LEUKEMIA
 7. LYMPHOMA
 8. ORAL CANCER
 9. SKIN CANCER
 10. UTERINE CANCER
 11. OVARIAN CANCER
 12. BLADDER CANCER
- B. Major Current And Emerging Cancer Diagnostic Tests
1. INTRODUCTION
 2. TUMOR MARKER CLASSIFICATION
 3. ACTH
 4. ALPHAFETOPROTEIN (AFP)
 5. BETA2 MICROGLOBULIN
 6. CA 153/27.29
 7. CA 19-9
 8. CA-125
 9. CALCITONIN
 10. CARCINOEMBRIONIC ANTIGEN (CEA)
 11. ESTROGEN AND PROGESTERONE RECEPTORS
 12. FERRITIN
 13. GASTRIN
 14. HUMAN CHORIONIC GONADOTROPIN (HCG)
 15. INSULIN
 16. NSE
 17. OCCULT BLOOD
 18. PAP SMEAR/HPV
 19. PROSTATIC ACID PHOSPHATASE (PAP)
 20. PROSTATESPECIFIC ANTIGEN (PSA)
 21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)
 22. T AND B LYMPHOCYTES
 23. TDT
 24. THYROGLOBULIN
 25. TISSUE POLYPEPTIDE ANTIGEN (TPA)
 26. BIOCHEMICAL TUMOR MARKERS

27. ONCOGENES

Abl/ablcr

AIB1

BCL-

BRCA1

CD44

Cfos

Cmyb

Cmyc

CYP

ErbB

HPC1

Nmyc

P40

P51

P53

PIK3CA

PTI

Ras

Reg

Sis

Src

28. POLYPEPTIDE GROWTH FACTORS

Basic Fibroblast Growth Factor

BetaTGF

Cachectin (TNT)

Calmodulin

ECFR

Nerve Growth Factor (NGF)

Epidermal Growth Factor (EGF)

Ornithine Decarboxylase

Transferrin

Transforming Growth FactorAlpha

29. ECTOPIC HORMONES

30. COLONY STIMULATING FACTORS

31. LYMPHOKINES

AlphaInterferon

B Cell Growth Factors

B Cell Growth Factor (BCGF)

GammaInterferon

Interleukin1 (IL1)

Macrophage Activating Factor

32. IMMUNOHISTOCHEMICAL STAINS

33. EMERGING TUMOR MARKERS

NAcetylglucosamine

Actin

AlphaActin

Antineuronal Antibodies

7B2

B72.3

Bax

BCDF9

BLCA-

Blood Group Antigens A,B,H

CA

CA 724/TAG-

CA

CA-

CA-

CAM

CAR-

CathepsinD

Chromogranin A and B

Cluster 1 Antigen

Cluster5/5A Antigen

CTA

CU18

DR-

DUPAN-

Endometrial Bleeding Associated Factor

Endostatin

Epithelial Membrane Antigen

Feulgen Hydrolysis

Fibronectin

FSH

(1>3)Lfucosyltransferase

GastrinReleasing Peptide (GRP)

GDCFP-

Glucagon
Glycoamines
H23
Her-
Human Carcinoma Antigen
HPA
HSP27
Intermediate Filaments
Cytokeratins/CK18/Cyfra 21-
Desmin
Gliofibrillary Acid Protein
Neurofilaments
Vimentin
KA
Kinases
KP16D3
LAI
Leukocyte Common Antigen
Lewis Antigens
Lysophosphatidic Acid (LPA)
Ma 695/Ma
MABDF3
MAG
ME1
Minactivin
MN/CA9
MSA
Mucin Cancer Antigen (MCA)
Multiple Tumor Suppressor
Myosin
NEA-130
NMP22
OA-519
Opiod Peptides
Pglycoprotein
Pancreatic Oncofetal Antigen (POA)
Placental Lactogen
PR92
Proliferative Index, Ki-67

Px
RB Inactivation/Deletion
Ret
SCCL
Selectin
Sialic Acid
Sialyl SSEA1/SLX
SN10
Somatostatin
TA-
TABA
Tachykinin
TAG
TPS
Troponin
Tubulin
VCAM
VEGF
Villen

C. Cancer Diagnostic Testing INSTRUMENTATION REVIEW and Market Needs

D. Current and Emerging Cancer Diagnostic Technologies

1. MONOCLONAL AND POLYCLONAL ANTIBODIES

2. IMMUNOASSAYS

3. MOLECULAR DIAGNOSTICS

4. CHROMOSOME ANALYSIS

a. Chronic Myelogenous Leukemia (CML)

b. Acute Myeloid Leukemia (AML)

c. Acute Lymphoblastic Leukemia (ALL)

d. Malignant Lymphomas Lymphoid Malignancies

e. Chronic Lymphocytic Leukemia (CLL)

f. Solid Cancers

g. Chromosomal Translocation and Oncogenes

5. ARTIFICIAL INTELLIGENCE

6. FLOW CYTOMETRY

7. TWO DIMENSIONAL GEL ELECTROPHORESIS (2DGE)

8. BIOSENSORS

9. COMPETING/COMPLEMENTING TECHNOLOGIES

E. Personal Testing

8. UK CANCER DIAGNOSTICS MARKET

- A. Executive Summary
- B. Business Environment
- C. Market Structure
- D. Market Size, Test Volume and Sales Forecasts by Market Segment, Major Supplier Sales and Market Shares by Test

9. COMPETITIVE PROFILES

Abbott
AdnaGen/Alere
Agilent Technologies
Applied Gene Technologies
Arca Biopharma
Beckman Coulter/Danaher
Becton Dickinson
Biomedical Diagnostics
bioMerieux
BioRad
CellSearch
Cepheid
Correlogic Systems/Vermillion
Decode Genetics
Diadexus
Diagnocure
Diasorin
Eiken Chemical
Elitech Group
Epigenomics
Enterix
Enzo Biochem
Exact Sciences
Fujirebio
Guided Therapeutics
Hologic/GenProbe
Kreatech/Leica
Kyowa Medex
Mackay Life Sciences

Myriad Genetics
OncoLab
OrthoClinical Diagnostics
Panacea Pharmaceuticals
Polartech
Polymedco
PreMD
Qiagen
Quest Diagnostics
Radient Pharmaceuticals
Roche
Scienion
Sequenom
Siemens Healthcare
Takara Bio
Targeted Diagnostics & Therapeutics
Tosoh
Thermo
Veridex
Wako Pure Chemicals
Wallac/PE
Zila

10. APPENDIX: MAJOR UNIVERSITIES AND RESEARCH CENTERS DEVELOPING CANCER DIAGNOSTIC TECHNOLOGIES AND APPLICATIONS

List Of Tables

LIST OF TABLES

Tumor Marker Classification

Major Companies Developing or Marketing ACTH Tests

Major Companies Developing or Marketing AFP Tests

Major Companies Developing or Marketing Beta2 Microglobulin Tests

Major Companies Developing or Marketing CA 153/27.29 Tests

Major Companies Developing or Marketing CA 199 Tests

Major Companies Developing or Marketing CA 125 Tests

Major Companies Developing or Marketing Calcitonin Tests

Major Companies Developing or Marketing CEA Tests

Major Companies Developing or Marketing Estrogen Receptor Tests

Major Companies Developing or Marketing Progesterone Receptor Tests

Major Companies Developing or Marketing Ferritin Tests

Major Companies Developing or Marketing Gastrin Tests

Major Companies Developing or Marketing HCG Tests

Major Companies Developing or Marketing Insulin Tests

Major Companies Developing or Marketing NSE Tests

Major Companies Developing or Marketing Occult Blood Tests

Major Companies Developing or Marketing PAP Smear/HPV Tests

Major Companies Developing or Marketing PAP Tests

Major Companies Developing or Marketing PSA Tests

Major Companies Developing or Marketing Lymphocyte Subclassification Tests

Biochemical Markers Potential Applications In Cancer Diagnosis

Oncogenes Potential Applications In Cancer Diagnosis

Major Companies Developing or Marketing Oncogene Tests

Growth Factors Potential Applications In Cancer Diagnosis

Colony Stimulating Factors Potential Applications in Cancer Diagnosis

Lymphokines Potential Applications In Cancer Diagnosis

Immunohistochemical Stains Potential Applications in Cancer Diagnosis

Executive Summary Table: U.K., Total Tumor Marker Test Volume and Sales Forecast
by Market Segment

U.K., Estimated Cancer Death Rates Per 100,000 Population

U.K., Laboratories Performing Tumor Marker Tests by Market Segment

U.K., Hospital Laboratories Performing Tumor Marker Tests by Bed Size

U.K., Commercial/Private Laboratories Performing Tumor Marker Tests by Annual Test
Volume

U.K., Total Tumor Marker Testing Volume Forecast by Market Segment
U.K., All Market Segments Major Tumor Marker Test Volume Forecast
U.K., Hospital Laboratories Major Tumor Marker Test Volume Forecast by Test
U.K., Commercial/Private Laboratories Major Tumor Marker Test Volume Forecast
U.K., Total Tumor Marker Sales Forecast by Market Segment
U.K., All Market Segments Major Tumor Marker Sales Forecast by Test
U.K., Hospital Laboratories Major Tumor Marker Sales Forecast by Test
U.K., Commercial/Private Laboratories Major Tumor Marker Sales Forecast by Test
U.K., ACTH Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., AFP Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Beta2 Microglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., CA 153/27.29 Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., CA 199 Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., CA125 Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Calcitonin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., CEA Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Chromogranin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., ColonSpecific Antigen Test Volume and Diagnostics Sales by Market Segment
U.K., Cytokeratins Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Estrogen Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Ferritin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Gastrin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., HCG Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Insulin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., NSE Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Occult Blood Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Parathyroid Hormone Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Progesterone Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., PAP Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., PSA Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., S100 Protein Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Serotonin Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Sialic Acid Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., TDT Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Thymidine Kinase Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Thyroglobulin Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., TPA Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Total Tumor Marker Sales and Market Shares Forecast

U.K., CEA Testing Market Diagnostics Sales by Major Supplier

U.K., PSA Testing Market Diagnostics Sales by Major Supplier

I would like to order

Product name: 2015-2019 U.S. Cancer Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies

Product link: <https://marketpublishers.com/r/2B2B115619AEN.html>

Price: US\$ 7,840.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2B2B115619AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

